Drug Profile
Ocifisertib - Treadwell Therapeutics
Alternative Names: CFI 400945 fumarate; CFI-400945Latest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator University Health Network
- Developer AstraZeneca; Canadian Cancer Trials Group; Treadwell Therapeutics; University Health Network
- Class Antineoplastics; Cyclopropanes; Ethers; Indazoles; Indoles; Morpholines; Small molecules; Spiro compounds
- Mechanism of Action PLK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Prostate cancer; Triple negative breast cancer
- Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Preclinical Diffuse large B cell lymphoma; Uterine leiomyoma
- No development reported Cancer
Most Recent Events
- 20 Feb 2024 CFI 400945 receives Orphan Drug status for Acute myeloid leukaemia in USA
- 15 Dec 2023 Efficacy and adverse events data from a phase I/II TWT-202 trial in Acute myeloid leukemia released by Treadwell Therapeutics
- 06 Dec 2023 Treadwell Therapeutics plans a pivotal trial in Acute myeloid leukemia in 2025